Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial

被引：0
|
作者：
Xu, R. [1 ]
Muro, K. [2 ]
Kim, T. W. [3 ]
Park, Y. S. [4 ]
Wang, W. [5 ]
Han, S-W. [6 ]
Kotaka, M. [7 ]
Deng, Y-H. [8 ]
Ahn, J. B. [9 ]
Nakamura, M. [10 ]
Ba, Y. [11 ]
Cho, S-H. [12 ]
Kato, T. [13 ]
Zhang, T. [14 ]
Lee, K-W. [15 ]
Matsuoka, H. [16 ]
Fang, W-J. [17 ]
Morita, S. [18 ]
Iwasa, S. [19 ]
Junichi, S. [20 ]
机构：
[1] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou, Guangdong, Peoples R China
[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[4] Samsung Med Ctr, Dept Med, Seoul, South Korea
[5] First Peoples Hosp Foshan, Dept Gastrointestinal Oncol, Foshan, Peoples R China
[6] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
[7] Sano Hosp, Gastrointestinal Canc Ctr, Surg, Kobe, Hyogo, Japan
[8] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[9] Yonsei Univ, Severance Hosp, Dept Internal Med, Seoul, South Korea
[10] Aizawa Hosp, Aizawa Comprehens Canc Ctr, Matsumoto, Nagano, Japan
[11] Tianjin Med Univ, Canc Inst & Hosp, Dept Digest Oncol, Tianjin, Peoples R China
[12] Chonnam Natl Univ Hosp, Hematol Oncol, Gwanju, South Korea
[13] Natl Hosp Org Osaka Natl Hosp, Colorectal Surg, Osaka, Japan
[14] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Abdominal Oncol, Wuhan, Hubei, Peoples R China
[15] Seoul Natl Univ, Bundang Hosp, Coll Med, Internal Med, Seongnam, South Korea
[16] Fujita Hlth Univ Hosp, Surg, Toyoake, Aichi, Japan
[17] Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
[18] Kyoto Univ, Med Stat & Bioinformat, Kyoto, Japan
[19] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[20] Tokai Cent Hosp, Kakamigahara, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
88O
引用
收藏
页数：2
相关论文
共 50 条
  • [31] UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
    E Marcuello
    A Altés
    A Menoyo
    E del Rio
    M Gómez-Pardo
    M Baiget
    British Journal of Cancer, 2004, 91 : 678 - 682
  • [32] A UGT1A1 genotype-guided dosing study of irinotecan in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus bevacizumab (BEV).
    Sharma, Manish
    Toffoli, Giuseppe
    Buonadonna, Angela
    Marangon, Elena
    Polite, Blase N.
    Frustaci, Sergio
    Innocenti, Federico
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [33] UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
    Marcuello, E
    Altés, A
    Menoyo, A
    del Rio, E
    Gómez-Pardo, M
    Baiget, M
    BRITISH JOURNAL OF CANCER, 2004, 91 (04) : 678 - 682
  • [34] The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
    Dias, M. M.
    Pignon, J-P
    Karapetis, C. S.
    Boige, V.
    Glimeliuss, B.
    Kweekel, D. M.
    Lara, P. N.
    Laurent-Puig, P.
    Martinez-Balibrea, E.
    Paez, D.
    Punt, C. J. A.
    Redman, M. W.
    Toffoli, G.
    Wadelius, M.
    McKinnon, R. A.
    Sorich, M. J.
    PHARMACOGENOMICS JOURNAL, 2014, 14 (05): : 424 - 431
  • [35] ECONOMIC EVALUATION OF THE UGT1A1 PHARMACOGENETIC TEST TO INFORM DOSE SELECTION OF IRINOTECAN-BASED CHEMOTHERAPY
    Shabaruddin, F. H.
    Elliott, R. A.
    Tappenden, P.
    Payne, K.
    VALUE IN HEALTH, 2011, 14 (07) : A252 - A252
  • [36] UGT1A1 PROMOTER GENOTYPE AND TOXICITY IN PATIENTS WITH ADVANCED COLORECTAL CANCER TREATED WITH IRINOTECAN-CONTAINING CHEMOTHERAPY
    Chiara, S.
    Gargiulo, L.
    Marroni, P.
    Serra, M.
    Tomasello, L.
    Pastrone, I.
    Paganuzzi, M.
    Notaro, R.
    ANNALS OF ONCOLOGY, 2004, 15 : 43 - 43
  • [37] Efficacy and safety of irinotecan-based chemotherapy in poor risk patients suffering from metastatic colorectal cancer
    Deptala, A.
    Magon, M.
    Omyla-Staszewska, J.
    Asendrych, A.
    Paluszewska, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism
    Hazama, Shoichi
    Nagashima, Atsushi
    Kondo, Hiroshi
    Yoshida, Shin
    Shimizu, Ryoichi
    Araki, Atsuhiro
    Yoshino, Shigefumi
    Okayama, Naoko
    Hinoda, Yuji
    Oka, Masaaki
    CANCER SCIENCE, 2010, 101 (03) : 722 - 727
  • [39] The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
    M M Dias
    J-P Pignon
    C S Karapetis
    V Boige
    B Glimelius
    D M Kweekel
    P N Lara
    P Laurent-Puig
    E Martinez-Balibrea
    D Páez
    C J A Punt
    M W Redman
    G Toffoli
    M Wadelius
    R A McKinnon
    M J Sorich
    The Pharmacogenomics Journal, 2014, 14 : 424 - 431
  • [40] Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations
    Ma, Xu
    Han, Sen
    Liu, Ying
    Liu, Jing-Tao
    Fang, Jian
    Zhang, Yan-Hua
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2020, 72 (11) : 1528 - 1535
12345